Top Page
Victrex
(LSE:VCT)
Victrex (VCT) vs. iShares MSCI United Kingdom ETF (EWC)
Victrex Business Overview & Revenue Model
Victrex Earnings Call Summary
Victrex Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 291.00M | 296.20M | 307.00M | 341.00M | 306.30M | 266.00M |
| Gross Profit | 139.50M | 134.30M | 162.60M | 174.70M | 157.00M | 141.10M |
| EBITDA | 69.70M | 69.70M | 96.00M | 110.60M | 110.30M | 85.00M |
| Net Income | 17.20M | 17.20M | 61.70M | 76.20M | 73.20M | 54.20M |
Balance Sheet | ||||||
| Total Assets | 592.00M | 592.00M | 626.60M | 641.60M | 615.30M | 549.50M |
| Cash, Cash Equivalents and Short-Term Investments | 29.30M | 29.30M | 33.50M | 68.80M | 112.40M | 73.10M |
| Total Debt | 50.40M | 50.40M | 50.20M | 32.10M | 15.90M | 7.10M |
| Total Liabilities | 130.40M | 130.40M | 125.60M | 151.00M | 103.60M | 68.50M |
| Stockholders Equity | 461.00M | 461.00M | 499.00M | 488.80M | 509.20M | 478.10M |
Cash Flow | ||||||
| Free Cash Flow | 50.90M | 51.40M | 2.30M | 34.50M | 85.20M | 44.50M |
| Operating Cash Flow | 83.50M | 84.00M | 40.80M | 80.00M | 127.10M | 69.40M |
| Investing Cash Flow | -35.40M | -35.40M | -32.30M | -16.20M | -83.20M | -29.50M |
| Financing Cash Flow | -50.80M | -51.90M | -32.80M | -82.40M | -41.70M | -38.70M |
Victrex Technical Analysis
Victrex Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | £3.18B | 9.00 | 15.96% | 4.00% | -9.10% | 239.75% | |
67 Neutral | £619.27M | 20.85 | 6.65% | 8.40% | 4.75% | -3.29% | |
64 Neutral | £132.06M | 12.14 | 8.02% | 3.78% | 1.12% | -0.70% | |
64 Neutral | £3.56B | 25.45 | 6.17% | 3.76% | 2.36% | -13.99% | |
64 Neutral | £957.89M | ― | 3.37% | 1.37% | -11.78% | -92.61% | |
61 Neutral | $10.31B | 6.29 | 0.76% | 2.95% | 3.36% | -36.41% | |
45 Neutral | £107.95M | ― | -7.26% | ― | -4.41% | 2.29% |
Victrex Corporate Events
Victrex plc has announced that as of 31 July 2025, its issued share capital consists of 87,052,107 ordinary shares, each carrying one vote. This update is crucial for shareholders to calculate their interests in the company accurately, ensuring transparency and compliance with regulatory requirements.
The most recent analyst rating on (GB:VCT) stock is a Hold with a £880.00 price target. To see the full list of analyst forecasts on Victrex stock, see the GB:VCT Stock Forecast page.
Norges Bank has increased its voting rights in Victrex PLC to 9.09%, up from a previous position of 8.81%. This acquisition of voting rights indicates a strengthened influence of Norges Bank in the company’s decision-making process, potentially impacting Victrex’s strategic direction and stakeholder interests.
The most recent analyst rating on (GB:VCT) stock is a Sell with a £10.00 price target. To see the full list of analyst forecasts on Victrex stock, see the GB:VCT Stock Forecast page.
Victrex plc announced that Vivienne Cox, the Chair of the company, has purchased 2,747 ordinary shares at £7.21 each on the London Stock Exchange. This transaction reflects a vote of confidence in the company’s future prospects and may positively influence stakeholder perception, reinforcing Victrex’s position in the high-performance polymer industry.
The most recent analyst rating on (GB:VCT) stock is a Sell with a £10.00 price target. To see the full list of analyst forecasts on Victrex stock, see the GB:VCT Stock Forecast page.
Victrex plc reported an 8% increase in sales volume for Q3 2025 compared to the previous year, driven by growth in Sustainable Solutions, although revenue decreased by 3% due to adverse sales mix and lower average selling prices. The Medical division, particularly the Spine segment, underperformed due to industry destocking and competitive pressures. The company is addressing challenges in its new China manufacturing facility and is on track for lower capital expenditure. Despite currency headwinds, Victrex maintains strong cost discipline and improvement actions, projecting high single-digit volume growth for the full year, with a focus on medium to long-term growth prospects.
The most recent analyst rating on (GB:VCT) stock is a Sell with a £10.00 price target. To see the full list of analyst forecasts on Victrex stock, see the GB:VCT Stock Forecast page.
Victrex plc has announced a leadership change with Jakob Sigurdsson retiring as Chief Executive after nearly eight years, to be succeeded by Dr. James Routh. Dr. Routh, who brings extensive experience from international companies in sectors aligned with Victrex’s markets, is expected to drive growth through focused strategies and innovation. The transition aims to maintain Victrex’s strong market position and unlock further growth potential, aligning with global megatrends and enhancing profitability.
The most recent analyst rating on (GB:VCT) stock is a Sell with a £10.00 price target. To see the full list of analyst forecasts on Victrex stock, see the GB:VCT Stock Forecast page.
Victrex PLC has announced that as of June 30, 2025, its issued share capital consists of 87,052,107 ordinary shares, each carrying one vote, with no shares held in treasury. This update is crucial for shareholders as it provides the denominator for calculating changes in their interests, ensuring transparency and compliance with FCA regulations.
The most recent analyst rating on (GB:VCT) stock is a Sell with a £10.00 price target. To see the full list of analyst forecasts on Victrex stock, see the GB:VCT Stock Forecast page.
Victrex plc announced that Janet Ashdown, a Non-Executive Director and Chair of the Remuneration Committee, has been appointed as a Non-Executive Director on the Board of Synthomer plc, effective 1 July 2025. This appointment is expected to enhance Victrex’s industry positioning by strengthening its leadership team with Ashdown’s extensive experience, including her previous roles at BP plc and Harvest Energy Ltd, while her responsibilities at Victrex remain unchanged.
The most recent analyst rating on (GB:VCT) stock is a Sell with a £1250.00 price target. To see the full list of analyst forecasts on Victrex stock, see the GB:VCT Stock Forecast page.
Victrex plc has announced the appointment of Investec Bank plc as a Joint Corporate Broker, joining J.P. Morgan Cazenove in this role. This strategic move is expected to enhance Victrex’s market positioning and potentially drive value for its stakeholders by leveraging Investec’s expertise alongside their existing broker.
The most recent analyst rating on (GB:VCT) stock is a Buy with a £16.80 price target. To see the full list of analyst forecasts on Victrex stock, see the GB:VCT Stock Forecast page.
Norges Bank has increased its stake in Victrex PLC, raising its voting rights from 7.43% to 8.81% as of May 30, 2025. This acquisition of voting rights signifies a growing interest in Victrex by a major institutional investor, potentially impacting the company’s strategic decisions and signaling confidence in its market position.
The most recent analyst rating on (GB:VCT) stock is a Hold with a £1491.00 price target. To see the full list of analyst forecasts on Victrex stock, see the GB:VCT Stock Forecast page.
Victrex PLC has announced that as of May 30, 2025, its issued share capital consists of 87,052,107 ordinary shares, each carrying one vote, with no shares held in treasury. This update on voting rights and capital structure is crucial for shareholders to determine their interests and any changes in their stakes in the company, reflecting Victrex’s commitment to transparency and regulatory compliance.
The most recent analyst rating on (GB:VCT) stock is a Hold with a £1491.00 price target. To see the full list of analyst forecasts on Victrex stock, see the GB:VCT Stock Forecast page.
Victrex PLC has announced a change in the breakdown of its voting rights following a transaction involving FIL Limited. The transaction, which occurred on May 22, 2025, resulted in FIL Limited holding a total of 9.7662% of voting rights in Victrex, a slight decrease from a previous position of 10.1%. This adjustment in voting rights could impact the company’s governance dynamics and influence its strategic decisions, reflecting FIL Limited’s significant stake in the company.
The most recent analyst rating on (GB:VCT) stock is a Hold with a £1491.00 price target. To see the full list of analyst forecasts on Victrex stock, see the GB:VCT Stock Forecast page.
Victrex plc announced that David Thomas, a Non-Executive Director, purchased 1,158 ordinary shares at £8.46 each on the London Stock Exchange. This transaction reflects confidence in the company’s strategic direction and potential for growth, reinforcing its position as a leader in innovative polymer solutions.
The most recent analyst rating on (GB:VCT) stock is a Hold with a £1491.00 price target. To see the full list of analyst forecasts on Victrex stock, see the GB:VCT Stock Forecast page.
Victrex reported a 16% increase in sales volumes for the first half of 2025, driven by strong performance in its Sustainable Solutions segment, despite challenges in the medical sector and currency headwinds. The company has upgraded its full-year volume guidance to high-single-digit growth, supported by operational improvements and strategic initiatives like Project Vista. However, underlying profit before tax was impacted by foreign exchange, sales mix, and operational challenges in China. Victrex remains focused on driving profitability and growth through cost control and enhanced market strategies, while also achieving a major milestone with its ‘Magma’ mega-programme in the energy industry.